2017
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Papp K, Bachelez H, Blauvelt A, Winthrop K, Romiti R, Ohtsuki M, Acharya N, Braun D, Mallbris L, Zhao F, Xu W, Walls C, Strober B. Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis. British Journal Of Dermatology 2017, 177: 1537-1551. PMID: 28600810, DOI: 10.1111/bjd.15723.Peer-Reviewed Original ResearchConceptsIncidence rateTreatment groupsInfection rateSpecific infection rateSevere psoriasisSerious infectionsExposure-adjusted incidence ratesIRs of infectionsMonoclonal antibodiesWeeks of treatmentOverall infection rateIncidence of infectionOesophageal candidiasisBiological therapyPsoriasis trialsAntifungal therapyClinical trialsIxekizumabCandida infectionsPatientsLong-term exposureInfectionPsoriasisIncidenceTrials
2013
Treatment of atopic dermatitis in pregnancy
Babalola O, Strober B. Treatment of atopic dermatitis in pregnancy. Dermatologic Therapy 2013, 26: 293-301. PMID: 23914886, DOI: 10.1111/dth.12074.Peer-Reviewed Original Research
2008
Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab
Marmon S, Strober B. Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. Journal Of Investigative Dermatology 2008, 128: 2567-2569. PMID: 18927537, DOI: 10.1038/jid.2008.291.Peer-Reviewed Original Research